Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
This study has been completed.
Study NCT00037609   Information provided by M.D. Anderson Cancer Center

First Received on May 17, 2002.   Last Updated on October 22, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasms
Metastases, Neoplasm
Additional conditions recognized in this trial
Neoplasm Metastasis
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Skin Diseases
Interventions listed in this trial
Capecitabine
Exisulind
Additional drug interventions recognized in this trial
Fluorouracil
Sulindac sulfone
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Anticarcinogenic Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Cell Pathways


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services